These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34818411)

  • 1. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients.
    Maillard A; Redjoul R; Klemencie M; Labussière Wallet H; Le Bourgeois A; D'Aveni M; Huynh A; Berceanu A; Marchand T; Chantepie S; Botella Garcia C; Loschi M; Joris M; Castilla-Llorente C; Thiebaut-Bertrand A; François S; Leclerc M; Chevallier P; Nguyen S
    Blood; 2022 Jan; 139(1):134-137. PubMed ID: 34818411
    [No Abstract]   [Full Text] [Related]  

  • 2. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Kuhlmann C; Mayer CK; Claassen M; Maponga T; Burgers WA; Keeton R; Riou C; Sutherland AD; Suliman T; Shaw ML; Preiser W
    Lancet; 2022 Feb; 399(10325):625-626. PubMed ID: 35063123
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis.
    Garcia P; Anand S; Han J; Montez-Rath ME; Sun S; Shang T; Parsonnet J; Chertow GM; Schiller B; Abra G
    J Am Soc Nephrol; 2022 Jan; 33(1):33-37. PubMed ID: 34645698
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals.
    Uprichard SL; O'Brien A; Evdokimova M; Rowe CL; Joyce C; Hackbart M; Cruz-Pulido YE; Cohen CA; Rock ML; Dye JM; Kuehnert P; Ricks KM; Casper M; Linhart L; Anderson K; Kirk L; Maggiore JA; Herbert AS; Clark NM; Reid GE; Baker SC
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
    Liu J; Bodnar BH; Padhiar NH; Khan AI; Meng F; Saribas S; Wang P; Wang X; McCluskey E; Shah S; Zhao H; Luo JJ; Hu WH; Ho WZ
    Clin Transl Med; 2021 Dec; 11(12):e644. PubMed ID: 34923762
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.
    Tenforde MW; Patel MM; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Botros M; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Naioti EA; Adams K; Lewis NM; Surie D; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):118-124. PubMed ID: 35085218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.
    Pagano L; Salmanton-García J; Marchesi F; López-García A; Lamure S; Itri F; Gomes-Silva M; Dragonetti G; Falces-Romero I; van Doesum J; Sili U; Labrador J; Calbacho M; Bilgin YM; Weinbergerová B; Serrano L; Ribera-Santa Susana JM; Malak S; Loureiro-Amigo J; Glenthøj A; Córdoba-Mascuñano R; Nunes-Rodrigues R; González-López TJ; Karlsson LK; Jiménez-Lorenzo MJ; Hernández-Rivas JÁ; Jaksic O; Ráčil Z; Busca A; Corradini P; Hoenigl M; Klimko N; Koehler P; Pagliuca A; Passamonti F; Cornely OA
    Blood; 2022 Mar; 139(10):1588-1592. PubMed ID: 34748627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
    Hall VG; Ferreira VH; Ku T; Ierullo M; Majchrzak-Kita B; Chaparro C; Selzner N; Schiff J; McDonald M; Tomlinson G; Kulasingam V; Kumar D; Humar A
    N Engl J Med; 2021 Sep; 385(13):1244-1246. PubMed ID: 34379917
    [No Abstract]   [Full Text] [Related]  

  • 13. Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant.
    Le Bourgeois A; Coste-Burel M; Guillaume T; Peterlin P; Garnier A; Imbert BM; Drumel T; Mahé B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Jullien M; Vantyghem S; Moreau P; Le Gouill S; Béné MC; Chevallier P
    Br J Haematol; 2022 Mar; 196(5):e38-e40. PubMed ID: 34671982
    [No Abstract]   [Full Text] [Related]  

  • 14. Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
    Kumar D; Ferreira VH; Hall VG; Hu Q; Samson R; Ku T; Ierullo M; Majchrzak-Kita B; Tomlinson G; Gingras AC; Humar A
    Ann Intern Med; 2022 Feb; 175(2):226-233. PubMed ID: 34807716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
    Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
    Front Immunol; 2021; 12():780594. PubMed ID: 34925359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell and Antibody Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients.
    Devresse A; Saad Albichr I; Georgery H; Yombi JC; De Greef J; Belkhir L; Mzougui S; Scohy A; Darius T; Buemi A; Goffin E; Kabamba B; Kanaan N
    Transplantation; 2021 Oct; 105(10):e142-e143. PubMed ID: 34310103
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Gastinne T; Le Bourgeois A; Coste-Burel M; Guillaume T; Peterlin P; Garnier A; Imbert BM; Drumel T; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Tessoulin B; Jullien M; Vanthygem S; Béné MC; Moreau P; Le Gouill S; Chevallier P
    Br J Haematol; 2022 Jan; 196(2):360-362. PubMed ID: 34476803
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very Low Immunization Rate in Kidney Transplant Recipients After One Dose of the BNT162b2 Vaccine: Beware not to Lower the Guard!
    Georgery H; Devresse A; Yombi JC; Belkhir L; De Greef J; Darius T; Buemi A; Scohy A; Kabamba B; Goffin E; Kanaan N
    Transplantation; 2021 Oct; 105(10):e148-e149. PubMed ID: 33988543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.